Literature DB >> 1400318

Activity and dimerization of human immunodeficiency virus protease as a function of solvent composition and enzyme concentration.

S P Jordan1, J Zugay, P L Darke, L C Kuo.   

Abstract

The activity of human immunodeficiency virus 1 (HIV-1) protease has been examined as a function of solvent composition, incubation time, and enzyme concentration at 37 degrees C in the pH 4.5-5.5 range. Glycerol and dimethyl sulfoxide inhibit the enzyme, while polyethylene glycol and bovine serum albumin activate the enzyme. When incubated at a concentration of 50-200 nM, the activity of the protease decreases irreversibly with an apparent first-order rate constant of 4-9 x 10(-3) min-1. The presence of 0.1% (w/v) polyethylene glycol or bovine serum albumin in the reaction buffer dramatically stabilizes enzyme activity. In the absence of prolonged incubation of the enzyme at submicromolar concentration, the specific activity of HIV-1 protease in buffers of either high or low ionic strength is constant over the enzyme concentration range of 0.25-5 nM, indicating that dissociation of the dimeric protease, if occurring, can only be governed by a picomolar dissociation constant. Similarly, the variation of the specific activity of HIV-2 protease over the enzyme concentration of 4-85 nM is consistent only with a dimer dissociation constant of less than 10 nM. We conclude that: 1) the assumption of a nondissociating HIV-1 protease is a valid one for kinetic studies of tight-binding inhibitors where nanomolar concentrations of the enzymes are employed; 2) stock protease solutions of submicromolar concentration in the absence of activity-stabilizing compounds may lead to erroneous kinetic data and complicate mechanistic interpretations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1400318

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

Review 1.  Pre-PCR processing: strategies to generate PCR-compatible samples.

Authors:  Peter Rådström; Rickard Knutsson; Petra Wolffs; Maria Lövenklev; Charlotta Löfström
Journal:  Mol Biotechnol       Date:  2004-02       Impact factor: 2.695

2.  Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants.

Authors:  W Shao; L Everitt; M Manchester; D D Loeb; C A Hutchison; R Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

3.  Identifying binding hot spots on protein surfaces by mixed-solvent molecular dynamics: HIV-1 protease as a test case.

Authors:  Peter M U Ung; Phani Ghanakota; Sarah E Graham; Katrina W Lexa; Heather A Carlson
Journal:  Biopolymers       Date:  2016-01       Impact factor: 2.505

4.  Analysis and characterization of dimerization inhibition of a multi-drug-resistant human immunodeficiency virus type 1 protease using a novel size-exclusion chromatographic approach.

Authors:  David A Davis; Irene R Tebbs; Sarah I Daniels; Stephen J Stahl; Joshua D Kaufman; Paul Wingfield; Michael J Bowman; Jean Chmielewski; Robert Yarchoan
Journal:  Biochem J       Date:  2009-04-15       Impact factor: 3.857

5.  Human immunodeficiency virus (HIV) type 1 transframe protein can restore activity to a dimerization-deficient HIV protease variant.

Authors:  Nathalie Dautin; Gouzel Karimova; Daniel Ladant
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

6.  Kinetics of the dimerization of retroviral proteases: the "fireman's grip" and dimerization.

Authors:  Marek Ingr; Tat'ána Uhlíková; Kvido Strísovský; Eva Majerová; Jan Konvalinka
Journal:  Protein Sci       Date:  2003-10       Impact factor: 6.725

7.  Potency and selectivity of inhibition of human immunodeficiency virus protease by a small nonpeptide cyclic urea, DMP 323.

Authors:  S Erickson-Viitanen; R M Klabe; P G Cawood; P L O'Neal; J L Meek
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

8.  Novel macromolecular inhibitors of human immunodeficiency virus-1 protease.

Authors:  Gabriella Miklóssy; József Tözsér; János Kádas; Rieko Ishima; John M Louis; Péter Bagossi
Journal:  Protein Eng Des Sel       Date:  2008-05-13       Impact factor: 1.650

9.  C-terminal residues of mature human T-lymphotropic virus type 1 protease are critical for dimerization and catalytic activity.

Authors:  János Kádas; Péter Boross; Irene T Weber; Péter Bagossi; Krisztina Matúz; József Tözsér
Journal:  Biochem J       Date:  2008-12-15       Impact factor: 3.857

10.  Importance of protease cleavage sites within and flanking human immunodeficiency virus type 1 transframe protein p6* for spatiotemporal regulation of protease activation.

Authors:  Christine Ludwig; Andreas Leiherer; Ralf Wagner
Journal:  J Virol       Date:  2008-03-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.